Michaeleen Doucleff

Michaeleen Doucleff is a reporter for NPR's Science Desk. She reports for the radio and the Web for NPR's global health and development blog, Goats and Soda. Doucleff focuses on disease outbreaks, drug development, and trends in global health.

In 2014, Doucleff was part of the team that earned a George Foster Peabody award for its coverage of the Ebola outbreak in West Africa. For the series, Doucleff reported on how the epidemic ravaged maternal health and how the virus spreads through the air. In 2015, Doucleff and Senior Producer Jane Greenhalgh reported on the extreme prejudices faced by young women in Nepal when they're menstruating. Their story was the second most popular one on the NPR website in 2015 and contributed to the NPR series on 15-year-old girls around the world, which won two Gracie Awards.

As a science journalist, Doucleff has reported on a broad range of topics, from vaccination fears and the microbiome to beer biophysics and dog psychology.

Before coming to NPR in 2012, Doucleff was an editor at the journal Cell, where she wrote about the science behind pop culture. Doucleff has a doctorate in chemistry from the University of Berkeley, California, and a master's degree in viticulture and enology from the University of California, Davis.

At least three coronavirus vaccines have been deemed effective. Some Western countries will start vaccination as early as this month. But it's unclear when less wealthy nations will get the vaccines.

Why does a disease hit some countries or regions hard and largely spares others?

For example, the virus that causes COVID-19 has surged so strongly in North and South America. But it has been less of a problem in Africa and many parts of Asia.

This week, the world heard encouraging news about a vaccine for COVID-19.

On Monday, the pharmaceutical company Pfizer, and its partner BioNTech, said their experimental vaccine appears to work – and work quite well. A preliminary analysis suggests the vaccine is more than 90 percent effective at preventing COVID-19 symptoms.

Health officials hope to start vaccinating some Americans in a few months.

Rich countries are rapidly claiming the world's lion's share of future doses of COVID-19 vaccine, creating deep inequalities in global distribution.

Despite an international agreement to allocate the vaccine equitably around the world, billions of people in poor and middle-income countries might not be immunized until 2023 or even 2024, researchers at Duke University predict.

As wildfires raged up and down the Pacific Coast last month, families across California and Oregon lived in – and breathed in — smoky, toxic air for weeks. Many days, the region's air quality ranked among the worst in the world.

Early in the coronavirus pandemic, air travel looked like a risky endeavor. Some scientists even worried that airplanes could be sites of superspreading events. For example, in March a Vietnamese businesswoman with a sore throat and a cough boarded a flight in London. Ten hours later, she landed in Hanoi, Vietnam; she infected 15 people on the flight, including more than half of the passengers sitting with her in business class.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

In case you were still procrastinating getting a flu shot this year, here's another reason to make it a priority.

There's a chance the vaccine could offer some protection against COVID-19 itself, says virologist Robert Gallo, who directs the Institute of Human Virology at the University of Maryland School of Medicine and is chairman of the Global Virus Network.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Editor's note: There has been speculation in the media and via Twitter that DNA fragments of the now-defunct 1918 flu pathogen could be preserved under the permafrost and might pose a potential threat to humans if the warming Earth continues to melt layers of frozen soil. A couple of years ago, NPR investigated that question: Could this pathogen — and others — be revived? A version of this story originally ran in January 2018.

Zac Peterson was on the adventure of a lifetime.

Updated on March 6 at 3:45 p.m.

It's the season for colds and flus — and a newly identified respiratory disease, COVID-19.

To cut your risk of catching a respiratory illness on your next flight, experts offer two pieces of common-sense advice: Wash your hands frequently and keep a distance from people who are sick.

Where to sit to prevent getting sick

A 2018 study suggests that to minimize contact with other passengers, you should pick a window seat and stay put.

Welcome to parenthood! For many of us, parenthood is like being air-dropped into a foreign land, where protohumans rule and communication is performed through cryptic screams and colorful fluids. And to top it off, in this new world, sleep is like gold: precious and rare. (Oh, so precious.)

Throughout human history, children were typically raised in large, extended families filled with aunts, uncles, grannies, grandpas and siblings. Adding another baby to the mix didn't really make a big dent.

Imagine for a minute: A company makes a vaccine that protects kids from a life-threatening disease but, with little warning, decides to stop selling it in the U.S.

That's exactly what happened last year in West Africa, for a vaccine against rotavirus — a disease that kills about 200,000 young children and babies each year.

Six years ago, I was traveling in India, working on a story about measles. I was visiting a public hospital in New Delhi, when I walked into the waiting room and saw the tiniest baby I had ever seen.

An elderly woman — perhaps a grandma — was cradling the newborn in her arms. The little baby was wrapped in a blanket, and a tiny knit cap covered her head, which wasn't much bigger than a small orange. The newborn could not have weighed more than four pounds.

The U.S. Food and Drug Administration just approved one of the most sought after vaccines in recent decades. It's the world's first vaccine to prevent dengue fever — a disease so painful that its nickname is "breakbone fever."

The vaccine, called Dengvaxia, is aimed at helping children in Puerto Rico and other U.S. territories where dengue is a problem.

Pages